The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors
John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY, comments on the ongoing development of JAK inhibitors in myeloproliferative neoplasms (MPNs), noting that two new JAK2 inhibitors are under clinical investigation and show promise in preclinical data. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
For those of us that thought the era of JAK inhibitors is done, that we have four approved JAK inhibitors, there’s no space for other JAK inhibitors, I think that story may not be over. So what I’m alluding to is the fact that there are two JAK2 inhibitors that are currently under clinical investigation that are getting a lot of attention. That’s the type 2 JAK2 inhibitor by Ajax, and then the Incyte JAK2V617F pseudokinase-specific inhibitor...
For those of us that thought the era of JAK inhibitors is done, that we have four approved JAK inhibitors, there’s no space for other JAK inhibitors, I think that story may not be over. So what I’m alluding to is the fact that there are two JAK2 inhibitors that are currently under clinical investigation that are getting a lot of attention. That’s the type 2 JAK2 inhibitor by Ajax, and then the Incyte JAK2V617F pseudokinase-specific inhibitor. And both oral drugs are JAK2 inhibitors, but variations on the theme with preclinical data that would suggest that they should be more potent, particularly in patients who might not have succeeded on a type 1 JAK inhibitor, which the four approved JAK inhibitors are, in terms of better down-regulating this signaling pathway and hopefully improving upon our responses. So we are anxious to see the readouts from the Phase I. So phase 1 is obviously our safety, but do we see signals of activity that would make us feel like this approach with these types of JAK2 may be better than the foundational approaches we’ve had with our current type one JAK inhibitors.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
